Cochrane Summariesbeta

Independent high-quality evidence for health care decision making
  • English
  • Deutsch AchtungWenn Sie die Sprache wechseln, gehen Ihre derzeitigen Suchergebnisse verloren!
  • Español WarningWhen switching the language you will loose your search results!

Search

Currently sorted by: Best match

Search results: 32

  1. Alkylating agents for Waldenstrom's macroglobulinaemia
    Waldenstrom's macroglobulinaemia (WM) is an uncommon B-cell lymphoproliferative disorder characterised by bone marrow infiltration and production of monoclonal immunoglobulin. It is a kind of non-Hodgkin's lymphoma which can lead to death. Alkylating agents are believed to be effective in treatment of Waldenstrom's macroglobulinaemia for alleviating ...
  2. Donor versus no donor comparison of hematopoietic cell transplantation for adult acute lymphoblastic leukemia in first complete remission
    An area of uncertainty in the care of patients with acute lymphoblastic leukemia (ALL) is the choice of treatment that is given after a complete remission is achieved with induction chemotherapy. Therapeutic alternatives include consolidation chemotherapy, autologous transplant (transplantation of a patient's own stem cells) or allogeneic transplant ...
  3. Bisphosphonates in multiple myeloma
    Multiple myeloma (also known as myeloma or plasma cell myeloma) is a B-cell malignancy, or more precisely, plasma cell neoplasm. Multiple myeloma cells migrate to the bone marrow and continuously multiply. Thus, the cancer grows inside or outside of the bones. The bone damage, or osteolytic lesions, may lead to fractures of the long bones or compression ...
  4. A comparison of the healthy donor's experience of donating their blood stem cells to a patient who is to receive a stem cell transplant as treatment for cancer of their blood (e.g. leukaemia)
    Blood stem cells are collected from a donor in two ways: either through a bone marrow harvest (direct retrieval of the stem cells from the donor's hip bones, under general anaesthetic) or a peripheral blood stem cell collection (retrieval of stem cells using a blood cell separator machine, following a course of granulocyte colony stimulating factor ...
  5. Although the addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy (R-chemo) has been shown to improve response rates and progression-free survival in patients with indolent or mantle cell lymphoma, the efficacy of R-chemo with respect t
    Study design: Meta-analysis of seven randomised controlled trials involving 1943 patients.Contribution: Patients treated with R-chemo had better overall survival, overall response, complete response, and disease control but more leukocytopenia and fever than patients treated with chemotherapy alone. R-chemo improved overall survival in patients with ...
  6. Second malignancy risk in Hodgkin's disease patients depends upon the choice of chemotherapy and/or radiotherapy as first-line treatment.
    Hodgkin's disease (HD) patients are usually treated initially with radiotherapy alone (RT; early stages only), chemotherapy alone (CT) or combined chemo-radiotherapy (CRT). A meta-analysis of data from 37 randomised trials including over 9000 patients was conducted. For early-stage patients, CRT resulted in longer survival and longer HD-free survival ...
  7. The use of colony-stimulating factors in the supportive care of patients with acute myelogenous leukemia (AML)
    Acute myelogenous leukemia (AML) is an aggressive, rare type of blood cancer manifested by infections, bleeding and a high rate of mortality. It requires immediate treatment with intensive chemotherapy and sometimes also with bone marrow transplantation. Infections are a major cause of mortality in AML patients since intensive chemotherapy lowers the ...
  8. Comparison of the two international standards of chemotherapy for patients with early unfavourable or advanced stage Hodgkin lymphoma
    Hodgkin lymphoma is a malignancy of the lymphatic system. It is one of the most common cancers in young adults, particularly in their third decade of life, but it occurs also in children and elderly people. Within the last fifty years it has become one of the most curable forms of cancer. To find the best treatment with the greatest efficacy and least ...
  9. Corticosteroid regimens for treatment of acute and chronic graft versus host disease (GvHD) after allogenic stem cell transplantation
    Corticosteroids are commonly used to treat acute and chronic graft-versus-host disease (GvHD) but their effect on length and quality of life of patients has not been studied systematically. In this systematic review, we tried to compare the effect of treatment regimens used for GvHD in the absence and presence of corticosteroids, or with different doses ...
  10. Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation
    Some types of blood cancer can be treated by transplanting stem cells from the patient's blood relatives or siblings. Unfortunately, transplanted stem cells (also called the 'graft') can sometimes induce an inflammatory reaction in the patient (or the 'host'). This reaction is called 'graft-versus-host disease' (GvHD), and once it occurs it is difficult ...

Pages

Summaries per page: